WO2001065994A2 - Methode et materiel d'evaluation de la faculte de reponse de patients cancereux a une chimiotherapie a antifolate - Google Patents

Methode et materiel d'evaluation de la faculte de reponse de patients cancereux a une chimiotherapie a antifolate Download PDF

Info

Publication number
WO2001065994A2
WO2001065994A2 PCT/IL2001/000212 IL0100212W WO0165994A2 WO 2001065994 A2 WO2001065994 A2 WO 2001065994A2 IL 0100212 W IL0100212 W IL 0100212W WO 0165994 A2 WO0165994 A2 WO 0165994A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
rfc
transport
mtx
folic acid
Prior art date
Application number
PCT/IL2001/000212
Other languages
English (en)
Other versions
WO2001065994A3 (fr
Inventor
Yehuda Assaraf
Statvit Drori
Original Assignee
Technion Research And Development Foundation Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research And Development Foundation Ltd. filed Critical Technion Research And Development Foundation Ltd.
Priority to US09/936,764 priority Critical patent/US20040101834A1/en
Priority to AU2001240998A priority patent/AU2001240998A1/en
Publication of WO2001065994A2 publication Critical patent/WO2001065994A2/fr
Publication of WO2001065994A3 publication Critical patent/WO2001065994A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Méthode d'évaluation de la faculté de réponse d'un patient cancéreux à une chimiothérapie contenant de l'antifolate, la méthode est mise à exécution par recherche d'une mutation ou de mutations dans un gène porteur de folates réduits (RFC) dans des cellules dérivées du patient.
PCT/IL2001/000212 2000-03-06 2001-03-06 Methode et materiel d'evaluation de la faculte de reponse de patients cancereux a une chimiotherapie a antifolate WO2001065994A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/936,764 US20040101834A1 (en) 2001-03-06 2001-03-06 Method of and kit for assessing responsiveness of cancer patients to antifolate chemotherapy
AU2001240998A AU2001240998A1 (en) 2000-03-06 2001-03-06 Method of and kit for assessing responsiveness of cancer patients to antifolate chemotherapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51967300A 2000-03-06 2000-03-06
US09/519,673 2000-03-06

Publications (2)

Publication Number Publication Date
WO2001065994A2 true WO2001065994A2 (fr) 2001-09-13
WO2001065994A3 WO2001065994A3 (fr) 2002-01-17

Family

ID=24069301

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2001/000212 WO2001065994A2 (fr) 2000-03-06 2001-03-06 Methode et materiel d'evaluation de la faculte de reponse de patients cancereux a une chimiotherapie a antifolate

Country Status (2)

Country Link
AU (1) AU2001240998A1 (fr)
WO (1) WO2001065994A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1556515A1 (fr) * 2002-10-10 2005-07-27 Precision Therapeutics Inc. Procedes d'evaluation de l'efficacite d'agents chimiotherapeutiques
EP1668337A2 (fr) * 2003-08-29 2006-06-14 Prometheus Laboratories, Inc. Methodes d'optimisation de la reactivite clinique a une therapie au methotrexate au moyen d'un profilage de metabolite et de la pharmacogenetique
WO2010055525A1 (fr) * 2008-11-17 2010-05-20 Technion Research & Development Foundation Ltd. Procédé pour prédire la réactivité d'un patient à une thérapie par antifolate
WO2011005504A1 (fr) * 2009-06-22 2011-01-13 Precision Therapeutics, Inc. Procédés de prédiction d'une réponse d'un patient atteint de cancer à une thérapie aux antifolates
US7972769B2 (en) 1996-07-12 2011-07-05 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GUO W. ET AL.: 'Mechanisms of methotrexate resistance in osteosarcoma' CLINICAL CANCER RESEARCH vol. 5, March 1999, pages 621 - 627, XP002944952 *
JANSEN G. ET AL.: 'A structurally altered human reduced folate carrier with increased folic acid trransport mediates a novel mechanism of antifolate resistance' JOURNAL OF BIOLOGICAL CHEMISTRY vol. 273, no. 46, 13 November 1998, pages 30189 - 30198, XP002944953 *
ROY K. ET AL.: 'A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectivity alters its interaction with folate analogues' JOURNAL OF BIOLOGICAL CHEMISTRY vol. 273, no. 5, 30 January 1998, pages 2526 - 2531, XP002944954 *
TAKEMURA Y. ET AL.: 'Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs' JAPANESE JOURNAL OF CANCER RESEARCH vol. 87, July 1996, pages 773 - 780, XP002944955 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7575868B2 (en) 1996-07-12 2009-08-18 Precision Therapeutics, Inc. Methods for assessing efficacy of chemotherapeutic agents
US7972769B2 (en) 1996-07-12 2011-07-05 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
EP1556515A1 (fr) * 2002-10-10 2005-07-27 Precision Therapeutics Inc. Procedes d'evaluation de l'efficacite d'agents chimiotherapeutiques
EP1556515A4 (fr) * 2002-10-10 2007-11-07 Precision Therapeutics Inc Procedes d'evaluation de l'efficacite d'agents chimiotherapeutiques
US7829288B2 (en) 2002-10-10 2010-11-09 Precision Therapeutics, Inc. Methods for assessing efficacy of chemotherapeutic agents
US8039213B2 (en) 2002-10-10 2011-10-18 Precision Therapeutics, Inc. Methods for assessing efficacy of chemotherapeutic agents
EP1668337A2 (fr) * 2003-08-29 2006-06-14 Prometheus Laboratories, Inc. Methodes d'optimisation de la reactivite clinique a une therapie au methotrexate au moyen d'un profilage de metabolite et de la pharmacogenetique
EP1668337A4 (fr) * 2003-08-29 2008-11-05 Prometheus Lab Inc Methodes d'optimisation de la reactivite clinique a une therapie au methotrexate au moyen d'un profilage de metabolite et de la pharmacogenetique
US7582282B2 (en) 2003-08-29 2009-09-01 Prometheus Laboratories Inc. Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics
WO2010055525A1 (fr) * 2008-11-17 2010-05-20 Technion Research & Development Foundation Ltd. Procédé pour prédire la réactivité d'un patient à une thérapie par antifolate
WO2011005504A1 (fr) * 2009-06-22 2011-01-13 Precision Therapeutics, Inc. Procédés de prédiction d'une réponse d'un patient atteint de cancer à une thérapie aux antifolates

Also Published As

Publication number Publication date
WO2001065994A3 (fr) 2002-01-17
AU2001240998A1 (en) 2001-09-17

Similar Documents

Publication Publication Date Title
Kluijtmans et al. Defective cystathionine beta-synthase regulation by S-adenosylmethionine in a partially pyridoxine responsive homocystinuria patient.
Simon et al. Gitelman's variant of Barter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na–Cl cotransporter
Grandchamp Acute intermittent porphyria
Vulliamy et al. The molecular basis of glucose-6-phosphate dehydrogenase deficiency
Sarfarazi et al. Assignment of a locus (GLC3A) for primary congenital glaucoma (Buphthalmos) to 2p21 and evidence for genetic heterogeneity
US6824972B2 (en) Diagnosis and treatment of medical conditions associated with defective NFkappa B(NF-κB) activation
Perrault et al. A retGC-1 mutation in autosomal dominant cone-rod dystrophy
Rothem et al. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines
Sumi et al. Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation
CA2454637A1 (fr) Moyens et methodes de traitement ameliore du cancer fondes sur mdr1
Hamdan-Khalil et al. In vitro characterization of four novel non-functional variants of the thiopurine S-methyltransferase
Valente et al. PARK6 is a common cause of familial parkinsonism
Kennan et al. A novel Asp380Ala mutation in the GLC1A/myocilin gene in a family with juvenile onset primary open angle glaucoma.
WO2001065994A2 (fr) Methode et materiel d'evaluation de la faculte de reponse de patients cancereux a une chimiotherapie a antifolate
CN101287846A (zh) 诊断血栓栓塞病和冠心病的方法
US20070254288A1 (en) Diagnostic methods for pain sensitivity and chronicity and for tetrahydrobiopterin-related disorders
Tischkowitz et al. Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer
WO1991012339A2 (fr) Association allelomorphe du gene recepteur de dopamine (d2) humaine dans des troubles compulsifs tels que l'alcoolisme
Ohye et al. Genomic organization and chromosomal localization of the human sepiapterin reductase gene
Pravenec et al. Identification of a mutation in ADD1/SREBP-1 in the spontaneously hypertensive rat
Miyachi et al. Expression of variant dihydrofolate reductase with decreased binding affinity to antifolates in MOLT-3 human leukemia cell lines resistant to trimetrexate
Affleck et al. Drosophila dihydrofolate reductase mutations confer antifolate resistance to mammalian cells
Matherly Human reduced folate carrier gene and transcript variants: functional, physiologic, and pharmacologic consequences
Kumagai et al. Thymidine phosphorylase gene mutation is not a primary cause of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)
Zachos et al. Evidence for loss of heterozygosity in human psoriatic lesions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 09936764

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)